These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31273010)

  • 1. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
    Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS
    Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
    Relph K; Annels N; Smith C; Kostalas M; Pandha H
    Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
    Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
    J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
    Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H
    Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
    Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
    Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
    Relph K; Arif M; Pandha H; Annels N; Simpson GR
    Methods Mol Biol; 2023; 2684():319-327. PubMed ID: 37410244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor microenvironment-modulating oncolytic adenovirus combined with GSK-3β inhibitor enhances antitumor immune response against bladder cancer.
    Yoon AR; Jiao A; Hong J; Kim B; Yun CO
    Front Immunol; 2024; 15():1360436. PubMed ID: 38812516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].
    Holm PS; Retz M; Gschwend JE; Nawroth R
    Urologe A; 2016 Mar; 55(3):356-63. PubMed ID: 26556269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
    Skelding KA; Barry RD; Shafren DR
    Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
    Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
    J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
    Li R; Zhang J; Gilbert SM; Conejo-Garcia J; Mulé JJ
    Nat Rev Urol; 2021 Sep; 18(9):543-555. PubMed ID: 34183833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
    Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer.
    Burke JM; Lamm DL; Meng MV; Nemunaitis JJ; Stephenson JJ; Arseneau JC; Aimi J; Lerner S; Yeung AW; Kazarian T; Maslyar DJ; McKiernan JM
    J Urol; 2012 Dec; 188(6):2391-7. PubMed ID: 23088985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications of coxsackievirus A21 in oncology.
    Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
    Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
    Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic
    Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM
    Curr Cancer Drug Targets; 2024; 24(9):967-974. PubMed ID: 38310465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
    Au GG; Lincz LF; Enno A; Shafren DR
    Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.